{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T13:43:48Z","timestamp":1791380628910,"version":"4.3.3"},"reference-count":34,"publisher":"MedWorks Media","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychopharmacol Bull"],"abstract":"<jats:p>Purpose\nTo determine whether recent methamphetamine use increases vancomycin clearance.\nMethods\nThis was a multi-center, retrospective, IRB-approved study at two tertiary care medical centers. Adult patients with a urine drug screen, \u22653 consecutive vancomycin doses, and an appropriately drawn vancomycin trough were assessed and classified as amphetamine positive or amphetamine negative. The primary outcome was vancomycin clearance.\nResults\n88 patients were included in the analysis, with 44 patients in each group. Vancomycin clearance was greater in the amphetamine positive group (94.54 vs. 86.84 mL\/min, p = 0.042, 95% CI 0.29\u201315.09). There was no significant difference in goal vancomycin trough achievement between groups (34.1% amphetamine positive vs. 43.2% amphetamine negative; p = 0.512). Per multifactorial logistic regression analysis, older age and male gender were associated with decreased vancomycin clearance, while higher BMI and cocaine positive urine drug screen were associated with increased vancomycin clearance.\nConclusion\nRecent methamphetamine use may increase vancomycin clearance. Larger prospective trials with protocolized vancomycin dosing strategies are needed to further elucidate the impact of methamphetamine use on attainment of goal vancomycin troughs in addition to the potential impact on vancomycin clearance.<\/jats:p>","DOI":"10.64719\/pb.4611","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T11:23:34Z","timestamp":1761045814000},"page":"23-35","source":"Crossref","is-referenced-by-count":0,"title":["Impact of Recent Methamphetamine Use on Vancomycin Clearance"],"prefix":"10.64719","volume":"50","author":[{"given":"S. Andrea","family":"Laguado","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Vadiei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kateryna","family":"Yenina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54175","published-online":{"date-parts":[[2025,8,12]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Jackson KA, Bohm MK, Brooks JT et al. [Accessed July 8, 2019];Invasive Methicillin-Resistant Staphylococcus Aureus Infections among Persons Who Inject Drugs \u2014 Six Sites, 2005\u20132016. 2018 https:\/\/www.cdc.gov\/mmwr\/volumes\/67\/wr\/mm6722a2.htm.","DOI":"10.15585\/mmwr.mm6722a2"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Rybak MJ, Le J, Lodise TP et al. Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm. 2020;77(11):835\u2013864. doi: 10.1093\/ajhp\/zxaa036. doi.","DOI":"10.1093\/ajhp\/zxaa036"},{"key":"ref3","unstructured":"Ferreira K. Evaluation of Vancomycin Dosing in Intravenous Drug Users Admitted to an Internal Medicine Service. In: Idsa. [Accessed July 8, 2019];2017 https:\/\/idsa.confex.com\/idsa\/2017\/webprogram\/Paper64873.html."},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Farr\u00e9 E, Villar\u00f3n P, Soy D, Carcelero E, Ribas J. PHC-029 Vancomycin pharmacokinetics in alcohol and intravenous drug abusers: Abstract PHC-029 table 1. Eur J Hosp Pharm. 2013;20(Suppl 1):A135.2\u2013A136. doi: 10.1136\/ejhpharm-2013-000276.374. doi.","DOI":"10.1136\/ejhpharm-2013-000276.374"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Rybak MJ, Albrecht LM, Berman JR, Warbasse LH, Svensson CK. Vancomycin pharmacokinetics in burn patients and intravenous drug abusers. Antimicrob Agents Chemother. 1990;34(5):792\u2013795. doi: 10.1128\/AAC.34.5.792. doi.","DOI":"10.1128\/AAC.34.5.792"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Novak SP, Kral AH. Comparing injection and non-injection routes of administration for heroin, methamphetamine, and cocaine users in the United States. J Addict Dis. 2011;30(3):248\u2013257. doi: 10.1080\/10550887.2011.581989. doi.","DOI":"10.1080\/10550887.2011.581989"},{"key":"ref7","unstructured":"Shaq Davis DEA. Meth, not opioids, top threat to Arizona. [Accessed September 18, 2019]; PinalCentral.com. https:\/\/www.pinalcentral.com\/arizona_news\/dea-meth-not-opioids-top-threat-to-arizona\/article_69e53534-08fd-59ea-9039-ec8a175587fe.html."},{"key":"ref8","unstructured":"NSDUH State Estimates. [Accessed June 21, 2020]; https:\/\/pdas.samhsa.gov\/saes\/state."},{"key":"ref9","unstructured":"Lipari RN. Key Substance Use and Mental Health Indicators in the United States: Results from the 2018 National Survey on Drug Use and Health. 2018;82 https:\/\/www.samhsa.gov\/data\/sites\/default\/files\/cbhsq-reports\/NSDUHNationalFindingsReport2018\/NSDUHNationalFindingsReport2018.pdf."},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Liu C, Bayer A, Cosgrove SE et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011;52(3):e18\u2013e55. doi: 10.1093\/cid\/ciq146. doi.","DOI":"10.1093\/cid\/ciq146"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Morrison AP, Melanson SEF, Carty MG, Bates DW, Szumita PM, Tanasijevic MJ. What proportion of vancomycin trough levels are drawn too early? Frequency and impact on clinical actions. Am J Clin Pathol. 2012;;137(3):472\u2013478. doi: 10.1309\/ajcpdsys0dvlkfoh. doi.","DOI":"10.1309\/ajcpdsys0dvlkfoh"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research Electronic Data Capture (REDCap) \u2013 A metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377\u2013381. doi: 10.1016\/j.jbi.2008.08.010. doi.","DOI":"10.1016\/j.jbi.2008.08.010"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Harris PA, Taylor R, Minor BL et al. The REDCap consortium: Building an international community of software platform partners. J Biomed Inform. 2019;95:103208. doi: 10.1016\/j.jbi.2019.103208. doi.","DOI":"10.1016\/j.jbi.2019.103208"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"KDIGO Update Work Group. KDIGO Clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease \u2014 mineral and bone disorder (CKD-MBD) Kidneys. 2017;2017;6(3):149\u2013154. doi: 10.22141\/2307-1257.6.3.2017.109030. doi.","DOI":"10.22141\/2307-1257.6.3.2017.109030"},{"key":"ref15","unstructured":"Kress JP, Hall JB. Approach to the Patient with Critical Illness. [Accessed July 8, 2020];In: Harrison\u2019s Principles of Internal Medicine. (20th ed). Chapter 293. McGraw-Hill Medical. https:\/\/accesspharmacy.mhmedical.com\/content.aspx?bookid=2129&sectionid=188731384."},{"key":"ref16","unstructured":"Thomas C. Dowling. Chapter e42: Evaluation of Kidney Function. In: Pharmacotherapy: A Pathophysiologic Approach. (10th ed) McGraw-Hill Medical. https:\/\/accesspharmacy.mhmedical.com\/content.aspx?bookid=1861&sectionid=134127006."},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Winter MA, Guhr KN, Berg GM. Impact of various body weights and serum creatinine concentrations on the bias and accuracy of the Cockcroft-Gault equation. Pharmacother J Hum Pharmacol Drug Ther. 2012;32(7):604\u2013612. doi: 10.1002\/j.1875-9114.2012.01098.x. doi.","DOI":"10.1002\/j.1875-9114.2012.01098.x"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Crass RL, Dunn R, Hong J, Krop LC, Pai MP. Dosing vancomycin in the super obese: Less is more. J Antimicrob Chemother. 2018;73(11):3081\u20133086. doi: 10.1093\/jac\/dky310. doi.","DOI":"10.1093\/jac\/dky310"},{"key":"ref19","unstructured":"Regression Statistics Solutions. [Accessed July 8, 2020]; https:\/\/www.statisticssolutions.com\/directory-of-statistical-analyses-regression-analysis\/regression\/"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Golper TA, Noonan HM, Elzinga L et al. Vancomycin pharmacokinetics, renal handling, and nonrenal clearances in normal human subjects. Clin Pharmacol Ther. 1988;43(5):565\u2013570. doi: 10.1038\/clpt.1988.74. doi.","DOI":"10.1038\/clpt.1988.74"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Wagner DJ, Sager JE, Duan H, Isoherranen N, Wang J. Interaction and transport of methamphetamine and its primary metabolites by organic cation and multidrug and toxin extrusion transporters. Drug Metab Dispos. 2017;45(7):770\u2013778. doi: 10.1124\/dmd.116.074708. doi.","DOI":"10.1124\/dmd.116.074708"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Meng L, Wong T, Huang S et al. Conversion from vancomycin trough concentration\u2013guided dosing to area under the curve\u2013guided dosing using two sample measurements in adults: Implementation at an academic medical center. Pharmacother J Hum Pharmacol Drug Ther. 2019;39(4):433\u2013442. doi: 10.1002\/phar.2234. doi.","DOI":"10.1002\/phar.2234"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"O\u2019Brien KA, Mok S. Evaluation of the safety of a vancomycin nomogram used to achieve target trough concentrations. Hosp Pharm. 2015;50(10):900\u2013910. doi: 10.1310\/hpj5010-900. doi.","DOI":"10.1310\/hpj5010-900"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Turner RB, Kojiro K, Won R, Chang E, Chan D, Elbarbry F. Prospective evaluation of vancomycin pharmacokinetics in a heterogeneous critically ill population. Diagn Microbiol Infect Dis. 2018;92(4):346\u2013351. doi: 10.1016\/j.diagmicrobio.2018.06.022. doi.","DOI":"10.1016\/j.diagmicrobio.2018.06.022"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"Bakke V, Sporsem H, Von der Lippe E et al. Vancomycin levels are frequently subtherapeutic in critically ill patients: a prospective observational study. Acta Anaesthesiol Scand. 2017;61(6):627\u2013635. doi: 10.1111\/aas.12897. doi.","DOI":"10.1111\/aas.12897"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Udy AA, Jarrett P, Stuart J et al. Determining the mechanisms underlying augmented renal drug clearance in the critically ill: Use of exogenous marker compounds. Crit Care. 2014;18(6):657. doi: 10.1186\/s13054-014-0657-z. doi.","DOI":"10.1186\/s13054-014-0657-z"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"Guay DRP, Vance-Bryan K, Gilliland S, Rodvold K, Rotschafer J. Comparison of vancomycin pharmacokinetics in hospitalized elderly and young patients using a Bayesian forecaster. J Clin Pharmacol. 1993;33(10):918\u2013922. doi: 10.1002\/j.1552-4604.1993.tb01922.x. doi.","DOI":"10.1002\/j.1552-4604.1993.tb01922.x"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"Ducharme MP, Slaughter RL, Edwards DJ. Vancomycin pharmacokinetics in a patient population: Effect of age, gender, and body weight. Ther Drug Monit. 1994;16(5):513\u2013518. doi: 10.1097\/00007691-199410000-00013. doi.","DOI":"10.1097\/00007691-199410000-00013"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"Kraemer T, Maurer HH. Toxicokinetics of amphetamines: Metabolism and toxicokinetic data of designer drugs, amphetamine, methamphetamine, and their N-alkyl derivatives. Ther Drug Monit. 2002;24(2):277\u2013289. doi: 10.1097\/00007691-200204000-00009. doi.","DOI":"10.1097\/00007691-200204000-00009"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"Riezzo I, Fiore C, De Carlo D et al. Side effects of cocaine abuse: Multiorgan toxicity and pathological consequences. Curr Med Chem. 2012;19(33):5624\u20135646. doi: 10.2174\/092986712803988893. doi.","DOI":"10.2174\/092986712803988893"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"Wolff K, Farrell M, Marsden J et al. A review of biological indicators of illicit drug use, practical considerations and clinical usefulness. Addiction. 1999;94(9):1279\u20131298. doi: 10.1046\/j.1360-0443.1999.94912792.x. doi.","DOI":"10.1046\/j.1360-0443.1999.94912792.x"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"Brahm NC, Yeager LL, Fox MD, Farmer KC, Palmer TA. Commonly prescribed medications and potential false-positive urine drug screens. Am J Health Syst Pharm. 2010;67(16):1344\u20131350. doi: 10.2146\/ajhp090477. doi.","DOI":"10.2146\/ajhp090477"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"Saitman A, Park H-D, Fitzgerald RL. False-positive interferences of common urine drug screen immunoassays: A review. J Anal Toxicol. 2014;38(7):387\u2013396. doi: 10.1093\/jat\/bku075. doi.","DOI":"10.1093\/jat\/bku075"},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"Miller DF, Garcia D, Kreys T-J, Phan SV, Vandenberg A, Garrison KL. Evaluating the quality of performance of medication reconciliation on hospital admission. Hosp Pharm. 2012;47(7):526\u2013531. doi: 10.1310\/hpj4707-526. doi.","DOI":"10.1310\/hpj4707-526"}],"container-title":["Psychopharmacology Bulletin"],"original-title":[],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:35:43Z","timestamp":1791315343000},"score":1,"resource":{"primary":{"URL":"https:\/\/medworksmedia.com\/pb-article\/impact-of-recent-methamphetamine-use-on-vancomycin-clearance\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,12]]},"references-count":34,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,8,12]]}},"URL":"https:\/\/doi.org\/10.64719\/pb.4611","relation":{},"ISSN":["2472-2448"],"issn-type":[{"value":"2472-2448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,12]]}}}